Showing 671-680 of 21412 results for "".
- Finerenone Associated with Lowered BP in T2D and DKDhttps://reachmd.com/news/finerenone-bp-t2d-dkd/2488082/Key Takeaways Finerenone initiation was associated with a generally lower systolic and diastolic blood pressure pattern over the first week in hypertensive patients with type 2 diabetes and diabetic kidney disease. The blood pressure decline often appeared within 24
- Linking Retinal Nonperfusion to Sensitivity Loss: New Insights for Diabetic Retinopathyhttps://reachmd.com/news/retinal-nonperfusion-sensitivity-loss-diabetic-retinopathy/2485332/A UK longitudinal cohort linked retinal capillary nonperfusion on ultra-widefield angiography to localized declines in retinal sensitivity on automated perimetry, s
- Innovations in AI: Transforming Diabetic Eye Care at The People's Health Clinichttps://reachmd.com/news/ai-diabetic-eye-care-peoples-health-clinic/2484529/The People's Health Clinic has deployed LumineticsCore
- Surprising Patterns in Infant Growth After Gestational Diabetes Exposurehttps://reachmd.com/news/surprising-patterns-in-infant-growth-after-gestational-diabetes-exposure/2468668/
- Sitting Time May Increase Risk of All-Cause Mortality in Adults with Diabeteshttps://reachmd.com/news/sitting-time-may-increase-risk-of-all-cause-mortality-in-adults-with-diabetes/2467725/
- DNA Sequencing Enhances Non-Invasive Early Detection of Gestational Diabeteshttps://reachmd.com/news/dna-sequencing-enhances-non-invasive-early-detection-of-gestational-diabetes/2457033/
- GLP‑1 Agents and Associations with Reduced Substance Use in a 600,000‑Patient Cohorthttps://reachmd.com/news/glp1-agents-and-associations-with-reduced-substance-use-in-a-600000patient-cohort/2485969/An observational analysis in U.S. Department of Veterans Affairs patients with type 2 diabetes found that starting a GLP-1 receptor agonist was associat
- GLP-1 Drugs Linked to Lower Alcohol Hospitalization Riskhttps://reachmd.com/news/glp-1-drugs-alcohol-hospitalization-risk/2488458/Key Takeaways Among adults with alcohol use disorder plus type 2 diabetes or obesity, initiation of semaglutide or tirzepatide was associated with lower observed risk of alcohol-related
- Cardiovascular and Safety Signals After GLP‑1 Discontinuation: Register Evidencehttps://reachmd.com/news/cardiovascular-and-safety-signals-after-glp1-discontinuation-register-evidence/2486323/A large register-based analysis of U.S. veterans with type 2 diabetes reported that stopping or interrupting GLP-1 receptor agonist therapy was associated with higher rates of major adver
- Navigating the Pathways of Glucose to Enhance Metabolic Healthhttps://reachmd.com/news/navigating-the-pathways-of-glucose-to-enhance-metabolic-health/2483007/Glucose transporters continue to influence the regulation of insulin secretion and broader metabolic processes. Their relevance in managing type 2 Diabetes and endocrine disorders is well-established. The mechanism of glucose transporters involves isoforms such as GLUT2 and GLUT4 fac